BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-documented adverse event from treatment with nitrogen-containing bisphosphonates (NBPs). During a preliminary histomorphometric study aimed at assessing the rate of bone remodeling in the jaws of patients with surgically resected BRONJ, we found a defect of bone mineralization (unpublished data). We hypothesized that osteomalacia could be a risk factor for BRONJ in patients taking NBPs. Therefore, we looked for static and dynamic histomorphometric evidence of osteomalacia in biopsies from subjects with and without BRONJ. METHODS: This case-control study used histomorphometric analysis of bone specimens of patients using NBPs (22 patients with BRONJ and 21 patients without BRONJ) who required oral surgical interventions for the treatment/prevention of osteonecrosis. Patients were given tetracycline hydrochloride according to a standardized protocol before taking bone biopsies from their jaws. Biopsies with evidence of osteomyelitis or necrosis at histology were excluded from the study. Osteomalacia was defined as a mineralization lag time >100 days, a corrected mean osteoid thickness >12.5 mm, and an osteoid volume >10%. RESULTS: In all, 77% of patients with BRONJ were osteomalacic compared with 5% of patients without BRONJ, according to histomorphometry. Because osteomalacia was found almost exclusively in NBP users with BRONJ, this is likely to be a generalized process in which the use of NBPs further deteriorates mechanisms of bone repair. CONCLUSIONS: Osteomalacia represents a new and previously unreported risk factor for disease development. This finding may contribute to a better understanding of the pathogenesis of this disease and help with the development of strategies to increase the safety of NBP administration.
BACKGROUND:Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-documented adverse event from treatment with nitrogen-containing bisphosphonates (NBPs). During a preliminary histomorphometric study aimed at assessing the rate of bone remodeling in the jaws of patients with surgically resected BRONJ, we found a defect of bone mineralization (unpublished data). We hypothesized that osteomalacia could be a risk factor for BRONJ in patients taking NBPs. Therefore, we looked for static and dynamic histomorphometric evidence of osteomalacia in biopsies from subjects with and without BRONJ. METHODS: This case-control study used histomorphometric analysis of bone specimens of patients using NBPs (22 patients with BRONJ and 21 patients without BRONJ) who required oral surgical interventions for the treatment/prevention of osteonecrosis. Patients were given tetracycline hydrochloride according to a standardized protocol before taking bone biopsies from their jaws. Biopsies with evidence of osteomyelitis or necrosis at histology were excluded from the study. Osteomalacia was defined as a mineralization lag time >100 days, a corrected mean osteoid thickness >12.5 mm, and an osteoid volume >10%. RESULTS: In all, 77% of patients with BRONJ were osteomalacic compared with 5% of patients without BRONJ, according to histomorphometry. Because osteomalacia was found almost exclusively in NBP users with BRONJ, this is likely to be a generalized process in which the use of NBPs further deteriorates mechanisms of bone repair. CONCLUSIONS:Osteomalacia represents a new and previously unreported risk factor for disease development. This finding may contribute to a better understanding of the pathogenesis of this disease and help with the development of strategies to increase the safety of NBP administration.
Authors: Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra Journal: J Oral Maxillofac Surg Date: 2009-05 Impact factor: 1.895
Authors: Robert R Recker; Pierre D Delmas; Johan Halse; Ian R Reid; Steven Boonen; Pedro A García-Hernandez; Jerzy Supronik; E Michael Lewiecki; Luis Ochoa; Paul Miller; Huilin Hu; Peter Mesenbrink; Florian Hartl; Juerg Gasser; Erik F Eriksen Journal: J Bone Miner Res Date: 2008-01 Impact factor: 6.741
Authors: Mario H Abu-Id; Patrick H Warnke; Joachim Gottschalk; Ingo Springer; Jörg Wiltfang; Yahya Acil; Paul A J Russo; Thomas Kreusch Journal: J Craniomaxillofac Surg Date: 2008-01-30 Impact factor: 2.078
Authors: Katherine D Crew; Elizabeth Shane; Serge Cremers; Donald J McMahon; Dinaz Irani; Dawn L Hershman Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: S Adami; S Giannini; G Bianchi; L Sinigaglia; O Di Munno; C E Fiore; S Minisola; M Rossini Journal: Osteoporos Int Date: 2008-06-13 Impact factor: 4.507
Authors: Kenneth W Lyles; Cathleen S Colón-Emeric; Jay S Magaziner; Jonathan D Adachi; Carl F Pieper; Carlos Mautalen; Lars Hyldstrup; Chris Recknor; Lars Nordsletten; Kathy A Moore; Catherine Lavecchia; Jie Zhang; Peter Mesenbrink; Patricia K Hodgson; Ken Abrams; John J Orloff; Zebulun Horowitz; Erik Fink Eriksen; Steven Boonen Journal: N Engl J Med Date: 2007-09-17 Impact factor: 91.245
Authors: Maria Fusaro; Giulia Vanessa Re Sartò; Maurizio Gallieni; Laura Cosmai; Piergiorgio Messa; Maurizio Rossini; Iacopo Chiodini; Mario Plebani; Pieter Evenepoel; Nicholas Harvey; Serge Ferrari; Jorge Cannata-Andía; Andrea Trombetti; Maria Luisa Brandi; Markus Ketteler; Thomas L Nickolas; John Cunningham; Syazrah Salam; Carlo Della Rocca; Aldo Scarpa; Salvatore Minisola; Fabio Malberti; Filomena Cetani; Mario Cozzolino; Sandro Mazzaferro; Luigi Morrone; Giovanni Tripepi; Martina Zaninotto; Maria Cristina Mereu; Maura Ravera; Giuseppe Cianciolo; Gaetano La Manna; Andrea Aghi; Sandro Giannini; Luca Dalle Carbonare Journal: Nutrients Date: 2022-04-22 Impact factor: 6.706